Semaglutide is a GLP-1 receptor agonist used in FDA-approved prescription products for specific metabolic and cardiovascular indications. Its approval does not extend automatically to compounded, salt-form, counterfeit, or “research” products sold under the same ingredient name.

Semaglutide at a glance

What is semaglutide?

Semaglutide activates the glucagon-like peptide-1 receptor. Depending on the approved product and label, it is used in type 2 diabetes, chronic weight management, and certain risk-reduction contexts. Product name and indication matter: the evidence and labeling for one formulation should not be copied onto another.

What does the evidence support?

Large randomized trials support clinically meaningful improvements in weight and metabolic outcomes for appropriate populations using approved products. Current labeling—not a social post or clinic advertisement—is the controlling source for who a product is indicated for and which warnings apply.

Risks and limitations

Approved semaglutide labels contain contraindications, warnings, and adverse-effect information that require individualized review. Gastrointestinal adverse effects are common. Labels and safety communications also address concerns involving gallbladder disease, pancreatitis, kidney injury associated with dehydration, hypoglycemia with some concurrent therapies, and other clinically important risks. The exact warnings vary by product and current label.

Approved versus compounded semaglutide

FDA does not approve compounded drugs or verify their safety, effectiveness, or quality before marketing. The agency has warned about dosing errors, unapproved salt forms, misleading equivalence claims, and adverse events involving non-FDA-approved GLP-1 products. An ingredient name on a label does not establish authenticity or equivalence.

What people report online

Community-reported—not proof: discussions commonly focus on appetite, weight change, gastrointestinal effects, plateaus, cost, access, discontinuation, and weight regain. These reports often omit diagnosis, product verification, concurrent lifestyle changes, and long-term follow-up.

Frequently asked questions

Is semaglutide FDA-approved for weight loss?

Wegovy is an FDA-approved semaglutide product with weight-management indications for specified populations. That does not mean every product marketed as semaglutide is FDA-approved or equivalent to Wegovy.

Primary sources

• DailyMed: Current Wegovy prescribing information
• FDA: Compounding and the FDA
• FDA: Concerns involving illegal imported GLP-1 ingredients

Educational information only; not individualized medical advice or treatment instruction.